All In Biotech

Drug Trial Radar · NCT07460375

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

A First-in-Human Phase 1/2, Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of Claudin18.2 (CLDN18.2)-Directed Antibody-Drug Conjugate (ADC) LCB02A in Patients With CLDN18.2-positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

191

Planned (sponsor's estimate)

Start

Oct 14, 2026

Primary completion

Feb 2030

Study completion Aug 2030

Sponsor

Lead sponsor
LigaChem Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
AntibodyChem Biosciences, Inc.
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

Conditions

  • Advanced Solid Tumors

Interventions

  • LCB02ADrug

    CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of LCB02A (Phase 1 and 2)Time frame: Up to 48 months
  2. Recommended Phase 2 dose of LCB02A (Phase 1)Time frame: Up to 24 months
  3. Objective response rate (Phase 2)Time frame: Up to 24 months

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Mass General Hospital

    Boston, Massachusetts · Not yet recruiting

  • START New York - Long Island

    Lake Success, New York · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Not yet recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Princess Margaret Hospital

    Toronto, Ontario, Canada · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • ASAN Medical Center

    Seoul, South Korea · Not yet recruiting

  • Samsung Medical Center

    Seoul, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.